| Literature DB >> 26682048 |
Ting Shi1, Evelyn Balsells1, Elizabeth Wastnedge1, Rosalyn Singleton2, Zeba A Rasmussen3, Heather J Zar4, Barbara A Rath5, Shabir A Madhi6, Stuart Campbell7, Linda Cheyenne Vaccari1, Lisa R Bulkow8, Elizabeth D Thomas3, Whitney Barnett4, Christian Hoppe5, Harry Campbell9, Harish Nair10.
Abstract
BACKGROUND: Respiratory syncytial virus (RSV) is the most common pathogen identified in young children with acute lower respiratory infection (ALRI) as well as an important cause of hospital admission. The high incidence of RSV infection and its potential severe outcome make it important to identify and prioritise children who are at higher risk of developing RSV-associated ALRI. We aimed to identify risk factors for RSV-associated ALRI in young children.Entities:
Mesh:
Year: 2015 PMID: 26682048 PMCID: PMC4676580 DOI: 10.7189/jogh.05.020416
Source DB: PubMed Journal: J Glob Health ISSN: 2047-2978 Impact factor: 4.413
Eligibility criteria for selection of studies in the systematic review
ALRI – acute lower respiratory infection, RSV – respiratory syncytial virus
List of the various definitions of risk factors for RSV–associated ALRI included in meta–analysis
| Risk factor | Definition |
|---|---|
| Gestational age <37 weeks | |
| Gestational age <33 weeks | |
| Birth weight <2.5 kg | |
| Male | |
| Mention of siblings or other children living in the household | |
| Maternal smoking during pregnancy | |
| Positive family history of asthma or atopy | |
| No parent having bachelor’s degree | |
| Education of primary caregiver: 1–7 y or no schooling | |
| <12 y maternal education | |
| <11 y maternal education | |
| Smokers in the household | |
| Attendance at daycare center | |
| Use of biomass fuels for cooking or a description of indoor smoke | |
| No breastfeeding | |
| >7 persons in household | |
| Twins or triplets | |
| Confirmed presence of HIV infection in child |
ALRI – acute lower respiratory infection, RSV – respiratory syncytial virus, HIV – human immunodeficiency virus, y – years
Figure 1Flow diagram for the selection of studies.
Characteristics of 27 included studies
| Study | Study period | Study design | Age | Case ascertainment | Case definition | Sample size | RSV detection | Risk factors included |
|---|---|---|---|---|---|---|---|---|
| May 2004–May 2005 | Prospective birth cohort | <1y | IP | ARI | 217 | NPS; PCR | PR, BF, S, PS, MS | |
| 1997–2003 | Case-control | <18m | IP | ARI | 15380 | RSV database | M, HOA, DCA, S, MS | |
| Jan 2006–Dec 2008 | Prospective birth cohort | <1y | IP, OP | ALRI | 298 | Nasal/throat swab; PCR | BF, M, HOA, PE, DCA, MS | |
| 1998–2002 | Cross-sectional | <4y | IP | P, B | 4847 | ICD–9 RSV codes | Altitude | |
| Oct 2002–Dec 2004 | Randomized controlled trial | <18m | IP, OP | ARI | NA | NA; IF | IAP | |
| May 2003–Apr 2007 | Birth cohort | <4y | C | ALRI | 469 | NPW; DFA | MB, PE, MA, C, S, PS | |
| Mar 1998–Dec 2004 | Prospective cohort | <6y | IP | ALRI | 39836 | NPA; IF | PR, HIV | |
| Oct 1996–Apr 1999 | Retrospective cohort | <2y | IP | ARI | NA | NPA; DFA/culture | PR, LBW, M | |
| Mar 2008 to Apr 2009 | Retrospective & prospective cohort | <1y | IP | B | 498 | NPA; IF | PR | |
| Jul 1996–Jun 1999 | Cross-sectional | <2y | IP | ARI | NA | NPA; PCR | PR | |
| Jul 2000–Dec 2004 | Retrospective cohort | <5y | IP | ALRI | 10913 | NA; PCR/culture | M, PE, MA, S | |
| Jan 1997–Jun 2004 | Case-control | <3y | IP | ALRI | 750 | NPA; DFA | PR, LBW, M, S | |
| Jul 1989–Jun 1993 | Retrospective cohort | <1y | IP | ARI | 3553 | NA | PR, M, PE, S, MS | |
| 1990–1994 | Case-control | <2y | IP | ALRI | 7632 | NPA; DFA | PR, LBW, S, MS | |
| Jul 1996–Jun 2000 | Case-control | <2y | IP | ALRI | 14343 | NPA; IF | PR, LBW, MB, M, | |
| June/July–October, 2003–2005 | Case-control | <2y | IP | B | 11411 | NPA; DFA | PR, MB, M, MS | |
| Oct 1993–Sep 1996 | Case-control | <3y | IP | ALRI | 542 | NPA; IF | BF, PE, C, S, S | |
| 1993–1995 | Case-control | <5y | IP | ALRI | 641 | NPA; IF | HOA, M, C, S, PS, M, LPW, IAP | |
| Oct–Apr, 2000–2004 | Case-control | ≤4y | IP | ALRI | 437 | Nasal sample; IF | PR, LBW, BF, M, HOA, PI, S, PS | |
| Oct 2006–Sep 2007 | Case-control | <3y | IP | ALRI | 68 | NPS; PCR | PR, BF, C, IAP, PS | |
| Apr 2012–Mar 2014 | Case-control | <5y | C | ALRI | 93 | NPS; PCR | C, M, PE, S, IAP, PS | |
| Mar 1997–Mar 1998 | Cross-sectional | 2–23m | IP | ALRI | 24000 | NPA; DFA | HIV | |
| Jan 2010–Dec 2011 | Cross-sectional | <5y | IP | ALRI | 835060 | NPA; PCR | HIV | |
| 1995–2012 | Cross-sectional | <1y | IP | ALRI | NA | NPA; DFA/culture | C, IAP, LPW | |
| 2000–2004 | Cross-sectional | <1y | IP | ALRI | NA | NPA; DFA/culture | LPW | |
| Mar 2012–Dec 2014 | Prospective cohort | <3y | C | ALRI | 159 | NPS; RT–PCR | PR, LBW, BF, M, HOA, PE, S, PS, MS, DCA, MA, C, IAP, PI | |
| Apr 2010–Mar 2014 | Prospective cohort | <5y | IP, OP | ALRI | 666 | NPS/NPA; RT–PCR | PR, LBW, M, C |
Case ascertainment: IP – inpatient, OP – outpatient; C – community. Case definition: ALRI –acute lower respiratory infection, ARI – acute respiratory infection, P – pneumonia, B – bronchiolitis. RSV detection: NPA – nasopharyngeal aspirate, NPS – nasopharyngeal swab, NPW – nasopharyngeal wash, PCR – polymerase chain reaction, IF – immunofluorescence, DFA – direct fluorescent antibody test, IFA – indirect fluorescent antibody test. Risk factors included: P – prematurity, LBW – low birth weight, BF – no/lack of exclusive breastfeeding, MB – multiple births, M – male, HOA – history of atopy, PE – low parental education, S – siblings, PS – passive smoking, MS – maternal smoking, DCA – daycare center attendance, MA – malnutrition, C – crowding, IAP – indoor air pollution, PI – previous illness, HIV – human immunodeficiency virus, LPW – lack of plumbed water, NA – not available, y – year, m – month
Meta–estimate of odds ratio for risk factors excluding studies with quality score ≤6.25 (ie, “low–quality”)
| Risk factor | Multivariable analysis | Multivariable and univariable analysis | ||
|---|---|---|---|---|
| No. of studies | Meta–estimate OR (95% confidence interval) | No. of studies | Meta–estimate OR (95% confidence interval) | |
| 2 | – | 7 | 1.96 (1.44–2.67) | |
| 2 | – | 5 | 1.91 (1.45–2.53) | |
| 6 | 1.32 (1.24–1.40) | 12 | 1.23 (1.13–1.33) | |
| 6 | 1.53 (1.20–1.95) | 11 | 1.60 (1.32–1.95) | |
| 4 | 1.34 (1.26–1.42) | 7 | 1.36 (1.24–1.50) | |
| 1 | – | 5 | 1.47 (1.16–1.87) | |
| 4 | 1.23 (0.73–2.09) | 6 | 1.40 (0.94–2.08) | |
| 4 | 1.40 (0.65–3.00) | 8 | 1.29 (0.96–1.73) | |
| 2 | – | 3 | 1.61 (0.98–2.64) | |
| 4 | 0.69 (0.35–1.37) | 5 | 0.81 (0.42–1.57) | |
| 1 | – | 3 | 2.24 (1.56–3.20) | |
| 1 | – | 3 | 1.94 (1.29–2.93) | |
OR – odds ratio